Medical Condition News

RSS

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

Special JHTR issue highlights ongoing CDC efforts to reduce population impact of TBI

Ongoing efforts by the Centers for Disease Control and Prevention to reduce the population impact of traumatic brain injury (TBI) are documented in the May/June issue of The Journal of Head Trauma Rehabilitation, official journal of the Brain Injury Association of America.

12 May 2015

UC Irvine study opens door to novel treatments for people with retinal damage

Driving down a dimly lit road at midnight can tax even those with 20/20 vision, but according to a recent UC Irvine study, the brain processes the experience no differently than if it were noon. The same study also reveals how quickly the brain adapts to vision loss, contradicting earlier research and opening the door to novel treatments.

12 May 2015

New study finds link between father's age at birth and child's risk of blood cancer as an adult

A new study links a father's age at birth to the risk that his child will develop blood and immune system cancers as an adult, particularly for only children. The study, which appears in the American Journal of Epidemiology, found no association between having an older mother and these cancers.

12 May 2015

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

In a major advance in the field of neuropsychiatry, researchers in the Vollum Institute at Oregon Health & Science University have illuminated how cocaine and amphetamines disrupt the normal functioning of the dopamine transporter in the brain.

12 May 2015

OSU scientists develop more accurate method to evaluate cancer risk of pollutants

Scientists at Oregon State University have developed a faster, more accurate method to assess cancer risk from certain common environmental pollutants.

12 May 2015

Study highlights potential new targets for development of novel cancer therapy

An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.

12 May 2015

New method may help determine potential indicator of stress, neurological disorders

A research collaboration between the universities of Oslo and Aarhus has resulted in the development of a new method with diagnostic potential. The new method that combines phase extraction with an enzymatic reaction may eventually be used for an improved and faster screening analysis of isatin as a potential indicator of stress and neurological disorders.

12 May 2015

Myopia on the rise across Europe, new study finds

Myopia or short-sightedness is becoming more common across Europe, according to a new study led by King's College London. The meta-analysis of findings from 15 studies by the European Eye Epidemiology Consortium found that around a quarter of the European population is short-sighted but it is nearly twice as common in younger people, with almost half (47 per cent) of the group aged between 25 and 29 years affected.

12 May 2015

Scientists find smooth muscle cells as major contributing factor to vascular stiffness

Increased vascular stiffness has been identified as an important part of hypertension in aging adults. Previous studies of aortic stiffness have focused on changes in structural proteins that alter the properties of vascular walls causing them to become rigid.

11 May 2015

Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Individuals with this altered gene have hereditary hypertension (high blood pressure) and at the same time a skeletal malformation called brachydactyly type E, which is characterized by unusually short fingers and toes. The effect on blood pressure is so serious that -- if left untreated -- it most often leads to death before age fifty.

11 May 2015

Walnut-enriched diet may slow colorectal tumor growth

A new animal study from Beth Israel Deaconess Medical Center, Harvard Medical School, led by Dr. Christos Mantzoros, indicates that a diet containing walnuts may slow colorectal tumor growth by causing beneficial changes in cancer genes.

11 May 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

Boehringer Ingelheim, Sutter Health announce health care innovation collaboration

Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today announced the start of a five-year research and health care innovation collaboration, which will explore and test the value of digital health solutions, mobile technologies, and insights from advanced data analytics in the delivery of health care.

11 May 2015

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

The Michael J. Fox Foundation for Parkinson's Research announces the acquisition of a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools — cell lines, plasmids, compounds and more — will accelerate biological study and drug development against this promising disease-modification target.

11 May 2015

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

11 May 2015

Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumps

Debiotech of Switzerland and iSense CGM, Inc. of the US, announced today having entered into an Agreement under which Debiotech has the option to acquire the exclusive rights on the iSense CGM product and technology for use with patch pumps for diabetes therapy. Financial terms and conditions of the Agreement are not disclosed.

11 May 2015

New scanning methods could help predict people vulnerable to schizophrenia

New scanning methods which map the wiring of the brain could provide a valuable new tool to predict people at risk of schizophrenia, according to a new study.

11 May 2015

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options.

11 May 2015

Medical Condition News

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Special JHTR issue highlights ongoing CDC efforts to reduce population impact of TBI

UC Irvine study opens door to novel treatments for people with retinal damage

New study finds link between father's age at birth and child's risk of blood cancer as an adult

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

OSU scientists develop more accurate method to evaluate cancer risk of pollutants

Study highlights potential new targets for development of novel cancer therapy

New method may help determine potential indicator of stress, neurological disorders

Myopia on the rise across Europe, new study finds

Scientists find smooth muscle cells as major contributing factor to vascular stiffness

Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Walnut-enriched diet may slow colorectal tumor growth

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Boehringer Ingelheim, Sutter Health announce health care innovation collaboration

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumps

New scanning methods could help predict people vulnerable to schizophrenia

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News